OSI-906 + erlotinib + placebo
Phase 2CompletedDevelopment Stage
Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
Mar 4, 2011 → Mar 11, 2015
About OSI-906 + erlotinib + placebo
OSI-906 + erlotinib + placebo is a phase 2 stage product being developed by Astellas Pharma for Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy. The current trial status is completed. This product is registered under clinical trial identifier NCT01186861. Target conditions include Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy.
Hype Score Breakdown
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01221077 | Phase 2 | Completed |
| NCT01186861 | Phase 2 | Completed |
Competing Products
20 competing products in Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy